REG - Theracryf PLC - Notice of Results

TheracryfAnnouncement

20/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240520:nRST9622Oa&default-theme=true

RNS Number : 9622O  Theracryf PLC  20 May 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of FY results and Presentation via Investor Meet Company

 

Alderley Park, 20 May 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma
plc, the clinical stage drug development company focussing on oncology and
neuropsychiatry, announces that the Company's full year financial results for
the year to 31 March 2024 will be released on Tuesday 28  May 2024.

 

The results will be available via the London Stock Exchange's Regulatory News
Service (RNS) and on the Investor Relations section of the Company's website:
www.theracryf.com/investors (http://www.theracryf.com/investors) .

 

Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via
the Investor Meet Company platform at 3pm on Tuesday 28 May 2024.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until 27
May 2024, 09:00 BST, or at any time during the live presentation. Investors
who already follow TheraCryf plc on the Investor Meet Company platform will
automatically be invited.

 

Investors can sign up to Investor Meet Company HERE
(https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

- Ends-

 

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Instinctif Partners                                         +44 207 457 2020

theracryf@Instinctif.com
 Melanie Toyne-Sewell / Jack Kincade

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications such as neurodevelopmental disorders, glioblastoma*, addiction,
anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate
compelling data sets to proof of concept and/or later phase II to partner its
clinical programmes with mid-size to large pharma. As well as a number of
industry partnerships with companies, including Stalicla, in neurodevelopment
disorders and has sourced programmes from companies such as Takeda and Shire,
the Company has worked with and has ongoing collaborations with major
universities, hospitals and government organisations such as the University of
Manchester, Sapienza (Università di Roma), Kings College London and
University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORARMJTMTBBBPI